PDE5-Is for the Treatment of Concomitant ED and LUTS/BPH

Epidemiologic data in adult men exhibit a strong relationship between erectile dysfunction (ED) and lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH), indicating that men affected by ED should also be investigated for LUTS/BPH and those presenting with storage or voi...

Full description

Saved in:
Bibliographic Details
Published in:Current bladder dysfunction reports 2013-06, Vol.8 (2), p.150-159
Main Authors: Gacci, M., Sebastianelli, A., Salvi, M., Vignozzi, L., Corona, G., McVary, K. T., Kaplan, S. A., Oelke, M., Maggi, M., Carini, M.
Format: Article
Language:English
Subjects:
BPH-Related Voiding Dysfunction (Y Kojima
BPH-Related Voiding Dysfunction (Y Kojima, Section Editor)
Geriatrics/Gerontology
Gynecology
Medicine
Medicine & Public Health
Section Editor
Urology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Epidemiologic data in adult men exhibit a strong relationship between erectile dysfunction (ED) and lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH), indicating that men affected by ED should also be investigated for LUTS/BPH and those presenting with storage or voiding LUTS should be investigated for co-morbid ED. Common pathophysiolgical mechanisms underlying both LUTS/BPH and ED, including alteration of NO/cGMP or RhoA/Rho-kinase signaling and/or vascular or neurogenic dysfunction, are potential targets for proposed phosphodiesterase type 5 inhibitors (PDE5-Is). Several randomized controlled trials and only a few reviews including all commercially available PDE5-Is demonstrated the safety and efficacy of these drugs in the improvement of erectile function and urinary symptoms, in patients affected either by ED, LUTS, or both conditions.
ISSN:1931-7212
1931-7220
DOI:10.1007/s11884-013-0184-9